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Abstract
Infectious diseases are important causes of morbidity and mortality globally. Epidemiologically, differences in the patterns of infectious
diseases and antimicrobial resistance exist across diverse geographical regions. In this review on infectious diseases in the Arabian Penin-
sula and Egypt, the epidemiology of tuberculosis, malaria and human immunodeﬁciency virus (HIV) infections will be addressed. The
challenges of the hepatitis C epidemic in Egypt and the epidemiology of this infection across the region will be reviewed. In recent
years, we have seen dengue endemicity become established, with major outbreaks in parts of the region. Emerging data also indicate
that, across the region, there is an increasing burden of antibiotic resistance, with endemicity in healthcare settings and dissemination
into the community. New challenges include the emergence of the Alkhurma haemorrhagic fever virus in Saudi Arabia. The annual Hajj
pilgrimage in Saudi Arabia serves as a model for the control of infectious disease in mass gatherings. As most of these countries con-
stantly experience a uniquely dynamic population inﬂux in the form of expatriate workers, tourists, or pilgrims, concerted regional and
international collaboration to address these public health concerns in a region that lies at the crossroads for the global spread of infec-
tious pathogens is imperative.
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Infectious diseases are important causes of morbidity and
mortality globally. Epidemiologically, differences in the pat-
terns of infectious diseases and antimicrobial resistance exist
across diverse geographical regions. In this review on infec-
tious diseases in the Arabian Peninsula and Egypt, the epidemi-
ology of tuberculosis, malaria and human immunodeﬁciency
virus (HIV) infections will be addressed, as the control of
these infectious diseases, which are targeted in the millenium
development goals, remains relevant in the region. Addition-
ally, the status of the hepatitis C epidemic, which affects mil-
lions of people in Egypt, with the potential for spread across
the region, will be discussed. The emergence of dengue
endemicity and the evolving trends of the newly described
Alkhurma virus in Saudi Arabia will be reviewed in particular,
as these two infectious diseases pose signiﬁcant public health
risks, because they are associated with outbreaks. We will
also review the burden of invasive pneumococcal infection in
the Arabian Peninsula and Egypt. The changing trends in anti-
biotic resistance will be highlighted by reviewing the available
data on extended-spectrum b-lactamase (ESBL)-producing
Enterobacteriaecae and methicillin-resistant Staphylococcocus
aureus (MRSA) from across the region.
Finally, the Hajj pilgrimage in Saudi Arabia will be used as
a model to highlight the challenges of infectious disease in
mass gatherings (MGs), as control measures used in this MG
can serve as a prototype for other MGs across the world.
Although the infection control interventions applied in this
MG may not necessarily cross over to what is needed to
control and prevent the discussed infectious diseases in the
countries of the Arabian Peninsula and Egypt, important
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lessons, such as the need for active surveillance, centralized
data collection, and analysis, and the development of regional
collaboration, can be learnt.
Geography of the Arabian Peninsula and
Egypt
The Arabian Peninsula and Egypt lie at the crossroads of Asia
and Europe. The Arabian Peninsula is the world’s largest
peninsula, and is bordered by the Persian Gulf and the Red
Sea. The countries that make up the Arabian Peninsula are
Bahrain, Kuwait, Oman, Qatar, the United Arab Emirates
(UAE), Yemen, and Saudi Arabia, with the last of these being
the largest. The oil-rich nations of Kuwait, Bahrain, Qatar,
the UAE, Oman (combined population: c. 13 million) and
Saudi Arabia (population: c. 28 million) constitute the Gulf
Cooperation Council (GCC) countries. In contrast to the
GCC countries, Yemen is a low-income nation (population:
c. 22.5 million), with one of the highest population growth
rates globally. Across the Red Sea is Egypt, one of the most
populous countries in the Middle East and the North African
region (population: c. 81 million). The above-mentioned
countries share a common language (Arabic) and close
cultural, religious and economic ties. In addition to cross-
border travel among these countries, most of them attract
signiﬁcant numbers of international travellers for tourism and
business. A large number of expatriates, particularly from the
Indian subcontinent, Southeast Asia, and Africa, work in the
GCC countries. Expatriates constitute c. 20% of the popula-
tion in Saudi Arabia, Oman and Bahrain, c. 48% in Kuwait,
c. 80% in the UAE, and c. 80% in Qatar (http://www.indexm-
undi.com). Saudi Arabia annually hosts 2–3 million people
from across the globe for the Hajj. Leisure travel abroad is
common among GCC nationals, particularly in the summer
months. This constant movement of people, which is facili-
tated by the ease of air travel, puts this region at the cross-
roads for the global spread of infectious pathogens.
For this review, we searched the PUBMED/MEDLINE
database for articles published in English from 1990 to 2012.
A literature search for each infectious disease covered in the
review was carried out for each country. The search param-
eters included the country name and terms for the region
(Arabian Gulf, Arabian Peninsula, Middle East, and Eastern
Mediterranean Region). These were combined with the fol-
lowing search parameters, as applicable: infectious disease,
names of speciﬁc infectious diseases (e.g. malaria), aetiologi-
cal agents of speciﬁc infectious disease, and antibiotic resis-
tance. Hand-searching of references listed in relevant articles
was also carried out. Where available, statistical data from
websites of the ministry of health for each country and from
websites of international organizations, including the WHO,
Eastern Mediterranean Region Ofﬁce, and United Nations,
were obtained.
Tuberculosis (TB)
The HIV/AIDS epidemic and the emergence of multidrug-
resistant TB (MDR-TB) and extensively drug-resistant TB
have contributed to bringing TB to centre stage in terms of
global health importance In 2011, an estimated 8.8 million
new TB cases with 1.1 million deaths globally were reported
by the WHO [1]. A comparison of WHO data [1] for 1990
and 2010 indicates that most countries of the Arabian
Peninsula and Egypt are showing a decreasing trend of TB
incidence and prevalence (Table 1). In 2010, the highest rates
were reported in Yemen and the lowest in the UAE [1]. The
seemingly increasing trend observed for Kuwait and the mar-
ginal increment in Saudi Arabia (Table 1) most probably
reﬂect increased screening and surveillance leading to early
detection, particularly among incoming expatriates.
In the GCC countries, expatriate workers from countries
with a high prevalence of TB contribute to the occurrence
of new cases and sustained TB transmission [2–5]. In Saudi
Arabia, the TB incidence rate among expatriates doubles that
for Saudi nationals and most non-Saudi patients originate
from countries with high TB endemicity [5,6]. Typing studies
in Oman have demonstrated a predominance of the strains
commonly found on the Indian subcontinent [7]. Similarly,
data from Kuwait suggest that new cases of active TB among
expatriates result from reactivation of infections acquired in
the home countries [8]. TB screening is part of the medical
examination requirement for residency in the GCC coun-
tries, and in the past those identiﬁed as sputum-positive
were deported. Although most countries have switched to a
TABLE 1. Trends in tuberculosis incidence and prevalence





1990 2010 1990 2010
Bahrain 28 23 34 25
Egypt 34 18 79 28
Kuwait 16 41 19 51
Oman 30 13 40 16
Qatar 45 38 56 45
Saudi Arabia 17 18 23 24
UAE 4.5 3.1 15 6.2
Yemen 137 49 277 71
Adapted from [1].
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policy of providing treatment, it has been suggested that a
lingering fear of deportation may deter low-income immigrant
workers from accessing services for diagnosis and treatment
[4]. Healthcare workers in Oman recently advocated early
detection and treatment without post-treatment deportation,
as well as the provision of adequate health insurance schemes,
particularly for low-income workers, as strategies for
improved health-seeking behaviours of expatriates [4].
The emergence of MDR-TB and extensively drug-resistant
TB are serious concerns in TB control. In a single-centre ret-
rospective study in the western region of Saudi Arabia
reported in 2001, 20% of isolates were multidrug-resistant [9].
However, recently reported data of 1124 isolates from seven
regions of the country revealed that 4.5% were multidrug-
resistant, and molecular characterization showed a high fre-
quency of combined rpoB531 and katG315 mutations [10,11].
These recent multicentre studies are reﬂective of the current
status of MDR-TB in Saudi Arabia. The reported data show
that 4% and 1% of isolates were multidrug-resistant in the
UAE and Kuwait, respectively [12,13]. In a nationwide study in
Yemen, the prevalence of MDR-TB was 3.0% and 9.4% among
new and previously treated cases, respectively [14]. In contrast
to data from the Arabian Peninsula, higher rates of MDR-TB of
16–44% have been reported in single-centre studies in Egypt,
and multicentre studies are needed to determine whether this
is occurring across the country [15,16].
The national TB control committees in these countries are
tasked with the implementation of policies to ensure TB pre-
vention, early diagnosis, and treatment, as well as the reporting
and collation of national TB data. However, more needs to be
done in terms of standardizing national reporting systems,
developing improved laboratory facilities for early detection of
active and latent TB, molecular characterization of isolates,
and, ultimately, the development of a regional database.
HIV
Epidemiological data on HIV infection in the countries of the
Arabian Peninsula and Egypt come mostly from point-preva-
lence surveys, mandatory screening, facility-based surveil-
lance, and surveys of high-risk groups; there is a paucity of
general population surveys of HIV prevalence [17]. This is
probably associated with the prevailing stigmatization of HIV
infection in these countries [18,19]. The current data indi-
cate that there is no generalized HIV epidemic in these
countries; however, epidemic foci may be present among
high-risk populations, such as intravenous drug users and
sexual contacts of HIV-positive patients [17].
The ﬁrst case of HIV in Saudi Arabia was identiﬁed in
1984, and screening of contacts of known HIV-positive
persons, blood and organ donors, intravenous drug users,
prisoners, patients with sexually transmitted infections and
those with clinical suspicion of HIV exposure is currently
carried out in Saudi Arabia [20]. In all GCC countries, HIV
testing is a prerequisite medical examination for expatriates
to obtain residency. From 1984 to 2003, 7807 HIV cases
were reported in Saudi Arabia, comprising of 1743 nationals
and 6064 non-Saudis [21]. Cases are concentrated in urban
areas, with most patients being males aged 15–49 years, and
acquisition of the virus being mainly via heterosexual contact
[20,21]. The predominant HIV-1 genetic subtype in Saudi
Arabia is HIV subtype C, although high strain diversity has
been observed [22,23]. Drug susceptibility testing of 63 HIV
isolates obtained from patients in Saudi Arabia from 2004 to
2008 showed that only 52% were sensitive to three classes
of antiretroviral drug [24]. Genotypic analysis also revealed
the presence of mutations associated with high-level resis-
tance to one or more of the nucleoside analogue reverse
transcriptase inhibitors in 41% of isolates [24].
From 1986 to 1996, 378 HIV-positive patients were identi-
ﬁed in Bahrain, with 49% of cases occurring in nationals, and
intravenous drug use was identiﬁed as the major risk factor
[25]. The HIV prevalence in Kuwait nationals is estimated to
be approximately 0.3/100 000 [26]. No published data on HIV
prevalence in the UAE were identiﬁed in the scientiﬁc litera-
ture, but it has been suggested that HIV seroprevalence could
be between 0.1% and 3% [27]. However, this ﬁgure could be
higher, as this country is continuing to evolve into a cosmopol-
itan centre of tourism and international commerce in the
region. In 2004, it was estimated that there were 4000–12 000
HIV-positive persons in Yemen, and current data indicate that
the prevalence of HIV is increasing, being reported as 0.2% in
2010 (https://www.unaids.org/en/dataanalysis/monitoringcoun
tryprogress/progressreports/2012countries/). The high rates
of poverty and unemployment, and changing societal norms
and values, place young people in this country at risk of acquir-
ing HIV [17]. Although the HIV/AIDS prevalence in Egypt is
reported to be <0.1%, the ﬁgure may well be higher, owing to
changing socio-economic trends. Although the HIV prevalence
remains on the lower side in the Arabian Peninsula and Egypt,
probably because of the conservative culture and the religious
and societal values, there is a need to address the lack of
knowledge and stigmatization of this infection. Recent studies
have shown that educational intervention targeting young peo-
ple is an effective approach [18,27]. In addition, there is a need
for a surveillance system for data collection and reporting of
the HIV prevalence in the general population.
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Malaria
Malaria is a major public health problem, and each year 300–
500 million cases are reported globally. Rigorous control
programmes in the 1960–1970s resulted in a malaria-free
status for most countries of the Arabian Peninsula, except
Saudi Arabia and Yemen [28]. The WHO certiﬁcation of
malaria-free status is indicative of sustained elimination of
endemic cases and those resulting from indigenous mos-
quito-borne transmission for at least three consecutive years.
However, imported malaria attributable to international tra-
vel and a large expatriate population from malaria-endemic
regions remains a concern.
In Bahrain, 1572 cases of imported malaria, mostly in
expatriates from the Indian subcontinent, were reported
from 1992 to 2001 [29]. However, the decline in the num-
ber of cases, from a peak of 282 cases in 1992 to 54 in
2001, and the observed reduction in vector breeding sites,
suggest that the potential for re-emergence of indigenous
transmission is negligible [29]. In the UAE, elimination of
indigenous transmission was achieved in 1997, but, as this
country is a major hub for international travel and business,
signiﬁcant numbers of imported malaria cases continue to be
reported. In 2007, 2117 cases were reported, and this ﬁgure
rose to 2696 in 2008 (http://www.moh.gov.ae/en/Statistics/
Pages/default.aspx). The majority of infections (>90%) were
caused by Plasmodium vivax, and were identiﬁed predomi-
nantly in patients from the Indian subcontinent. During
1988–1991, 15.7–25.3% of malaria cases in the UAE were in
patients from neighbouring Oman [30]. However, from 2006
to 2008, there was only one case of malaria imported from
Oman (http://www.moh.gov.ae/en/Statistics/Pages/default.aspx).
This is not surprising, as Oman attained malaria-free status,
and the last report of malaria acquired by indigenous trans-
mission was in 2003 [28]. However, as in the UAE, an
increasing trend of imported malaria from 615 cases in 2004
to 898 in 2009 has been reported in Oman [28]. In Saudi
Arabia, c. 3.1 million people live in areas of active malaria
foci in the south-west of the country [28]. In 2002, of the
3074 conﬁrmed malaria cases, 47.8% (1471) were imported
cases [28]. In 2009 and 2010, 96% and 98% of cases, respec-
tively, were imported [28]. With this signiﬁcant reduction of
local transmission of malaria achieved over the past decade,
Saudi Arabia is now classiﬁed as being in the pre-elimination/
elimination phase of malaria endemicity.
Identiﬁcation of ancient DNA for Plasmodium falciparum in
Egpytian mummies suggests that malaria has been present in
Egypt since antiquity [31]. Whereas WHO data show that all
malaria cases since 1998 have been imported malaria, other
reports indicate that the Al-Fayoum Governorate in the
north-western part of Egypt remains an area of high malaria
risk in Egypt, owing to a unique combination of hydrogeology
and soil variables, plus the presence of a highly efﬁcient mos-
quito vector [28,32,33]. In sharp contrast to other countries
in the Arabian Peninsula, all reported cases of malaria in
Yemen were attributable to local transmission [28]. Up to
69% of the population live in areas of high transmission
(‡1 case/1000), with 99% of conﬁrmed infections being
attributable to P. falciparum [34]. Signiﬁcantly higher infection
rates are seen in the rural areas, and severe malaria accounts
for up to 20% of paediatric admissions [34,35]. In Yemen,
4.9 deaths/100 000/year and 43 000 disability-adjusted life-
years lost were attributed to malaria in 2004 [36]. As this
infection places a high burden on the meager health services
of this low-resource nation, further studies are needed to
clearly deﬁne the epidemiological pattern and identify tar-
geted intervention strategies for those at the greatest risk.
Viral Haemorrhagic Fevers
Dengue fever
Dengue-like disease was ﬁrst described in the Arabian Penin-
sula in c. 1870–1873 [37]. Serologically conﬁrmed cases of
dengue fever were not reported until the latter part of the
20th century, and the need for evaluation of the epidemiol-
ogy of this infection in the Arabian Peninsula was ﬁrst high-
lighted with the 1984 description of dengue haemorrhagic
fever in a traveller who had recently been to Yemen [38].
Although the vector (Aedes aegypti) is found across the
region, the occurrence of dengue as a public health concern
is limited to Saudi Arabia and Yemen. The ﬁrst documented
outbreak of dengue fever in Saudi Arabia was in 1994, and
the infection is now endemic in the western and southern
regions [39,40]. By 2008, 2500 conﬁrmed infections, with 59
cases of dengue haemorrhagic fever, 18 of dengue shock syn-
drome, and 12 deaths, were documented in three major out-
breaks in Saudi Arabia [41]. Similar trends were recorded in
Yemen, with up to three epidemics between 1994 and 2008
[41]. The most recent outbreak in 2010 resulted in approxi-
mately 100 000 infections and 200 deaths (Dengue/DHF
update 2010(41); http://www.promedmail.org). The recent
report from Italy, in which primary dengue virus infection
was identiﬁed in two patients who had recently travelled to
Egypt, suggests dissemination across the region and beyond
[42].
In Saudi Arabia, the predominant serotypes associated
with early outbreaks were dengue type 2 and type 1. In
1997, dengue type 3 emerged as the predominant serotype
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[39]. Phylogenetic studies of isolates collected from 1994 to
2006 showed that these three serotypes continue to pre-
dominate, with more than one serotype being identiﬁable
during outbreaks [40]. No new genotypes of dengue type 2
and type 3 have been identiﬁed, but the dengue type 1 virus
identiﬁed during the 1994 and 2006 outbreaks was of a
different genotypic lineage, suggestive of re-introduction of
the dengue type 1 virus into the country [40]. Although phy-
logenetic studies of isolates from Yemen have not been
reported, the dengue virus from an Italian patient who
acquired the infection in Yemen in 2010 showed 98–99%
homology to those from Saudi Arabia [43].
The annual inﬂux of Hajj pilgrims from around the world
into Saudi Arabia sets the stage for the introduction of new
dengue virus genotypes into the country. Additionally, the
potential dissemination into other countries by returning pil-
grims who acquire the virus while in Saudi Arabia is a global
health issue. With the ease of travel between Saudi Arabia,
other countries in the Arabian Peninsula and Egypt, the
potential for spread of the dengue virus across the region is
of concern. Concerted regional and international collabora-
tion to evaluate the epidemiology and determinants of den-
gue virus infection, identify potential hotspots and develop
strategic control measures are needed.
Alkhurma virus
Alkhurma haemorrhagic fever virus (AHFV) is a tick-borne
ﬂavivirus that was ﬁrst described in 1995 in Saudi Arabia
[44]. AHFV was successfully isolated in 1999, and complete
genome sequence analysis revealed that it is closely related
to the Kyaasanur Forest disease virus, with 89% homology
[45,46]. A clinical presentation with acute febrile illness, hep-
atitis, haemorrhagic manifestations, encephalitis and a case-
fatality rate of 25% has been reported for severe cases [47].
However, a recent report indicates that patients with AHFV
might exhibit subclinical illness manifesting with mild symp-
toms or be asymptomatic [48].
From 2001 to 2003, 20 laboratory-conﬁrmed cases of
AHFV illnesses were identiﬁed in Makkah, Saudi Arabia,
including four cases during the 2001 Hajj [47]. AHFV has also
been identiﬁed in Jizan and Najran in the southern region of
Saudi Arabia [48–50]. The recent identiﬁcation of seroposi-
tive persons from the northern and eastern regions of Saudi
Arabia suggests wider dissemination in the country [50,51].
Epidemiological studies suggest that AHFV is transmitted
from livestock to humans via arthropod vectors or via direct
contamination of a skin wound with the blood of infected
animals [45]. Hence, those in occupations associated with
contact with livestock, e.g. herdsmen and butchers, are at
risk of AHFV infection. Transmission via ingestion of unpas-
teurized contaminated milk has been reported, and there is
no evidence of human-to-human transmission [45].
To date, there are no reports of AHFV in other countries
of the Arabian Peninsula. It remains unknown whether this is
because of a true absence of this infection in the rest of the
region or because cases are being missed or misdiagnosed.
However, reports from Italy have described three cases of
AHFV in patients with a recent travel history to Egypt, which
suggests that wider dissemination of AHFV across the region
exists [52,53]. Further studies are warranted to fully under-
stand the epidemiology of AHFV infection and map the geo-
graphical distribution across the region. Identiﬁcation of the
range of arthropod vectors and the transmission patterns, as
well as clearer understanding of viral pathogenicity and the
natural history of the infection, are needed if we are to
develop appropriate strategies to limit the dissemination of
this emerging infectious disease.
Hepatitis C Virus (HCV)
It is estimated that, globally, c. 1 person out of every 50 is
infected with HCV. The HCV prevalence in Egypt is one of
the highest in the world, with a reported rate of 14.9%
[54,55]. It is estimated that approximately 100 000–500 000
new infections occur annually, and the annual incidence rate
reported by the Ministry of Health is 6.9/1000 persons
[55,56]. A recent survey of 500 healthy schoolchildren in
Alexandria demonstrated a seroprevalence rate of 5.8%, and
75% of HCV-positive children had viraemia [57]. A male pre-
ponderance has been shown, particularly in rural areas,
where there are higher prevalence rates [58]. The predomi-
nant HCV type, accounting for 90% of infections in Egypt, is
HCV genotype 4 [59,60]. The emergence of the HCV
epidemic in Egypt has been linked to the widespread use of
parenteral tartar emetic and the utilization of unsterilized
needles and re-used glass syringes during the schistosomiasis
eradication campaign of the 1950–1980s. However, the con-
tinued rising incidence of HCV infection in Egypt suggests a
possible role of other healthcare-associated risk factors.
Dental treatment has recently been identiﬁed as a signiﬁcant
risk factor for HCV infection in children in Egypt [61]. Blood
transfusion has been identiﬁed as a contributory factor for
HCV in those aged >20 years in a high-prevalence rural area
[62]. A better understanding of the dynamics of disease
acquisition in the community is needed, as recently reported
data from a tertiary hospital for liver diseases demonstrated
that most HCV infections among healthcare workers
resulted from community rather than hospital exposures
[63].
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In contrast to the situation in Egypt, the reported data on
hepatitis C prevalence in countries of the Arabian Peninsula
mostly concern high-risk groups and blood donors. The
reported HCV prevalence rates among haemodialysis
patients are 9.24% in Bahrain, 26.5% in Oman, 23% in the
UAE, 44.6% in Qatar, 33.8% in Yemen, and 18–46% in Saudi
Arabia [64]. In surveys of healthy blood donors, HCV positivity
rates were 0.94% and 1.1% in Oman and Qatar, respectively
[65,66]. A retrospective hospital-based study in Qatar
revealed an HCV incidence of 6.3/100 000, which is higher
than that reported for other GCC countries (Oman, 0.1/
10 000; UAE, 0.7/1000; Saudi Arabia, 1.0/1000) [66]. This high
rate was associated with expatriate workers from the Indian
subcontinent, who acquired the disease in their home coun-
tries. As in Egypt, HCV genotype 4 is predominant in the Ara-
bian Peninsula; however, other HCV genotypes, including 1a,
1b, and 3, are also circulating in the population [67–70].
Egypt is a major tourist destination, and the GCC coun-
tries host a large Egyptian diaspora. Thus, the HCV epi-
demic in Egypt has the potential for regional spread across
the Arabian Peninsula and global dissemination to other
countries. In Egypt, the health authorities have instituted a
programme to treat symptomatic patients with chronic
HCV infection. There is also a prevention programme con-
sisting of public awareness campaigns and the implementa-
tion of infection control policies in healthcare facilities.
Surveys to determine the prevalence of HCV in the gen-
eral population in the Arabian Peninsula are needed. Fur-
thermore, a concerted multipronged approach of health
education, early detection and improved infection control
practices is needed across the region to limit the spread
of this epidemic.
Invasive Streptococcus pneumoniae Infection
The burden of pneumococcal invasive disease in the region
remains signiﬁcant, particularly in the paediatric age group,
with incidence rates of 3.4–53.5/100 000/year in children
aged ‡5 years [71]. S. pneumoniae was identiﬁed as the caus-
ative agent in 30% of meningitis cases in Yemen, 16% in the
UAE, 19–21% in Kuwait, 13% in Qatar, 23–31% in Saudi Arabia,
and 21–30% in Egypt [71]. In a prospective study carried out
across Saudi Arabia from 2000 to 2004, the predominant
serotypes identiﬁed in children were serotypes 14, 23F, 6B,
and 19F [72]. In Egypt, data obtained from 13 hospitals
across the country between 1998 and 2003 identiﬁed sero-
types 6B, 6A, 14, 5 and 23F as being predominant among
children aged <2 years and serotypes 6A, 6B and 19F as
being predominant in those aged 2–5 years [73]. In Kuwait,
nationwide data collected from 2004 to 2005 revealed a pre-
dominance of serotypes 23F, 14, 19A and 6A in the paediat-
ric age group [74]. In a recent review of pneumococcal
disease in the Arabian Peninsula and Egypt, Shibl et al. [71]
concluded that 61–69% of serotypes associated with invasive
disease in children aged £5 years in the region were poten-
tially covered by the seven-valent pneumococcal conjugate
vaccine. The current practice of administration of the 13-
valent pneumococcal conjugate vaccine to children at ages 2,
4, 6 and 12 months in parts of the region is expected to
contribute to a reduction in the burden of invasive pneumo-
coccal disease.
There is a considerable burden of penicillin resistance, as
analysis of studies from the region shows that the propor-
tions of resistant isolates are 20–78% in Saudi Arabia, 21–
43% in the UAE, 49–52% in Egypt, 64% in Kuwait, 40% in
Qatar, and 14% in Yemen [71]. Up to 30% of S. pneumoniae
isolates in the UAE exhibited macrolide resistance, which is
a higher rate than the 8–26% reported in other studies in
the region, and the reason for this is yet to be elucidated
[71,75]. In addition, up to 21% of isolates in the UAE were
multidrug-resistant, as compared with 14% reported from
Yemen [75,76]. To better understand the pneumococcal dis-
ease burden and enable comparison of data across the
region, Shibl et al. [71] have recommended the use of stan-
dardized reporting mechanisms and uniform surveillance
methods.
Antibiotic Resistance: ESBLs and Emerging
Carbapenemases
ESBL-producing pathogens are now recognized globally as
aetiological agents of nosocomial and community-acquired
infections. The emergence of ESBL-producing pathogens
habouring the CTX-M (cefotaximase-Munich) and NDM-1
(New Delhi metallo-b-lactamase) genotypes has brought
about a shift in ESBL epidemiology, and created new treat-
ment challenges [77,78]. The prevalence of ESBL varies from
the 6% reported in Saudi Arabia to the 67% reported in
Egypt (Table 2). However, comparison of reported data from
within the same country and between countries in the region
is difﬁcult, as there is no uniﬁed surveillance or reporting
system in place, and published studies show variations in
patient populations, specimen types, and identiﬁed bacteria
(Table 2). Nevertheless, it is apparent that ESBL-producing
pathogens are now entrenched as important agents of anti-
microbial resistance in the region. The increasing occurrence
of community-acquired infections and faecal carriage in
healthy individuals is of concern [79–81].
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There are limited data on the molecular characterization
of ESBL-producing isolates circulating in these countries.
Reports from a limited number of studies indicate that iso-
lates harbouring the blaCTX-M genotype are increasingly being
implicated in nosocomial infections, including outbreaks and
community-acquired infections [80–83]. Emerging data from
across the region indicate that the proportion of ESBL-pro-
ducing isolates habouring blaCTX-M is as high as 83–94.5% in
the UAE [81,84], 77.9% in Kuwait [85], and 38.9–100% in
Egypt [86–88]. In Saudi Arabia, two studies have reported
blaCTX-M detection in 34% and 71% of Enterobacteriaceae
[89,90]. ESBL-producing isolates circulating in the region
show evidence of multidrug resistance, and a high prevalence
of acquired quinolone resistance determinants with a pre-
dominance of aac(6¢)-1b-cr in Enterobacteriaceae isolates has
recently been reported in Saudi Arabia [91]. Twenty-one iso-
lates that haboured qnrA or qnrB were found to be positive
for aac(6¢)-1b-cr and blaCTX-M-15 [91]. A previous report from
Kuwait had identiﬁed qnr in ESBL-positive Enterobacter and
Citrobacter isolates [92].
Although most studies continue to report sensitivity to car-
bapenems, isolates exhibiting carbapenemase resistance are
emerging in the region. NDM-1 was ﬁrst identiﬁed in 2008,
and the spread of NDM-1-producing isolates has been associ-
ated with patients with prior hospitalization in the Indian sub-
continent [93,94]. It has been suggested that the Middle East
region might be a secondary reservoir for the spread of patho-
gens harbouring blaNDM-1 [94]. Poirel et al. [95] reported the
ﬁrst identiﬁcation of NDM-1-producing isolates in the Arabian
Peninsula and the Middle East. The two NDM-1-positive Klebsi-
ella pneumoniae isolates identiﬁed in Oman were clonally unre-
lated with one recovered from a patient from India and the
second from an Omani patient with no previous travel [95].
The recent identiﬁcation of 11 NDM-1 producers, ﬁve OXA-
48 producers and one NDM-1 plus OXA-181 producer in a
cohort of 22 carbapenem-resistant enterobacterial isolates
identiﬁed in Oman from 2010–2011 suggests dissemination of
carbapenemase producers in the country [96]. Between 2010
and 2011, blaNDM-1-positive K. pneumoniae isolates were
recovered from two patients in the intensive-care unit of a











[101] Saudi Arabia 2001–2003 Inpatients Klebsiella pneumoniae (bacteraemia) 38.5 (20/26) Not performed
[102] Saudi Arabia, Egypt 2001–2002 Inpatients Enterobacteriaceae 18.6 and 38.5 Not performed
[103] Saudi Arabia 2002–2003 Inpatients Enterobacteriaceae and non-fermenting
Gram-negative bacilli
4.8 (156/3231) Not done
[104] Saudi Arabia 2003–2004 Inpatients/outpatients Escherichia coli, K. pneumonia,
Enterobacter, Pseudomonas
aeruginosa (urinary isolates)
8.9 (204/2302) Not performed
[105] Saudi Arabia 2003–2005 Inpatients E. coli, K. pneumonia 11 (268/2455) Not performed
[106] Saudi Arabia 2003–2004 Inpatients Enterobacteriaceae (from blood
culture only)
15.8 (95/601) Not performed
[107] Saudi Arabia 2004–2007 Inpatients/outpatients K. pneumoniae 10.4 (34/328) Not performed
[80] Saudi Arabia 2004–2005 Inpatients/outpatients Enterobacteriaceae 6 (409/6750) Not performed
[89] Saudi Arabia 2007 Inpatients K. pneumoniae 55 (220/400) blaCTX-M: 34.1%
blaTEM: 84.1%;
blaSHV: 97.3%
[108] Kuwait 2003 Inpatients Enterobacteriaceae, Pseudomonas,
Stenotrophomonas
7.5 (264/3529) Not performed
[109] Kuwait 2002–2005 Inpatients Enterobacteriaceae 31.7 (1018/3215) Not performed
[110] Kuwait 2005–2007 Outpatients E. coli, K. pneumoniae (urinary isolates) 17.4 (1544/8839) Not performed
[111] Oman 2005 Inpatients (paediatrics) E. coli, K. pneumoniae 14.9 (13/87) Not performed
[112] UAE 2005–2006 Inpatients Enterobacteriaceae 41 (53/130) Not performed
[84] UAE 2008 Inpatients E. coli, K. pneumoniae 36 (240/662) blaCTX-M-15: 82.9% (199/240)
blaSHV-28: 12.1% (29/240—all
K. pneumoniae)
[83] Bahrain 2005–2006 Inpatients/outpatients Enterobacteriaceae 22.6 (2695/11 886) Not performed
[88] Egypt 2007–2008 Inpatients/outpatients Enterobacteriaceae 16%(83/520) blaCTX-M-15: all
74 isolates tested
[87] Egypt 2006 Inpatients (adult ICU) Enterobacteriaceae (bloodstream
infections)
64.7 (33/51) blaSHV: 61.1%
blaTEM: 55.6%
blaCTX-M1: 38.9%
[113] Eygpt 2005–2006 Inpatients (neonatal ICU) K. pneumoniae 67 (18/27) blaSHV-2: 100%
blaSHV-1: 44%
[114] Eygpt 2005–2007 Inpatients Gram-negative pathogens
(blood cultures)
44 (363/816) Not performed
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tertiary-care facility in Kuwait [97]. One isolate was from a
patient who had just returned from India, and the second was
from an elderly Kuwait male with no prior travel history.
Although both patients were not in the intensive-care unit at
the same time, the isolates were clonally related. In the UAE,
the recovery of Acinetobacter baumanii habouring blaNDM-2 in a
patient who had previously been hospitalized in Egypt suggests
that regional dissemination is ongoing [98]. The occurrence of
outward spread from the region into Europe has been
reported, with the isolation of A. baumanii harbouring NDM-1
in patients transferred from Egypt to hospitals in Germany and
the Czech republic [99,100]. We were unable to identify pub-
lished literature on the emergence of NDM-1-positive isolates
in other countries in the region. It thus appears that NDM-1
producers are now emerging and spreading in the region, so
coordinated regional surveillance and reporting of antibiotic
resistance is even more imperative.
MRSA
Across the Arabian Peninsula and Egypt, MRSA appears to
be endemic in healthcare facilities, and emerging data suggest
an increasing burden of community-acquired MRSA
(CA-MRSA) causing nosocomial infections. However, com-
parison of data from different hospitals/countries in the
region is difﬁcult, as there is no centralized surveillance or
reporting system, and there are differences in methodologies
and patient populations in different studies.
In Saudi Arabia, MRSA rates ranging from 8% to 49% have
been reported in studies from various healthcare facilities,
with an increasing trend of MRSA rates [115–120]. In a ter-
tiary-care hospital in Riyadh, the incidence rate for hospital-
acquired MRSA infection increased from 0.8/1000 admissions
in 2000 to 2.3/1000 admissions in 2004 [119]. A report from
another healthcare facility indicated a similar increasing trend
of MRSA infections, as MRSA isolates constituted 2% of all
Staphylococcocus aureus isolates identiﬁed in 1999, increasing
to 8% in 2003 [120]. The increasing burden of CA-MRSA in
Saudi Arabia is reﬂected in a report from the eastern prov-
ince, which showed an increasing CA-MRSA incidence, rising
from 9.9/10 000 admissions in 2001 to 67/10 000 admissions
in 2008 [121]. Of additional concern is the occurrence of
severe CA-MRSA invasive infections in children [122,123]. In
Kuwait, 32% of Staphylococcocus aureus isolates from 13 hos-
pitals were MRSA, including epidemic MRSA-15 [124]. In
Oman, the incidence of MRSA infection at the burns unit of
a major hospital increased from 48% in 1995 to 52% in 1996
[125]. The increasing incidence of MRSA from 2003 to 2008
in a tertiary-care hospital in the UAE has been associated
with the establishment of CA-MRSA clones in the hospital
[126]. The evidence suggests that, in Bahrain, variants of a
single MRSA clone are present in the hospital and commu-
nity [127]. From 2007 to 2008, 13.2% of Staphylococcocus aur-
eus isolates from patients with bacteraemia at a general
hospital in Qatar were reported as MRSA [128]. In Egypt,
data from nine participating hospitals in the Antibiotic Resis-
tance Surveillance and Control in the Mediterranean Region
project showed that 33% of the Staphylococcocus aureus
blood culture isolates were methicillin-resistant, increasing to
50% in 2004 and 63% in 2005 [129]. More recently, data
from active surveillance in 2006–2007 in three university
hospitals in Egypt showed that 60% of Staphylococcocus aureus
bloodstream infections were caused by MRSA [130]. Data
from the limited typing indicate that internationally recog-
nized MRSA clones are circulating in the region (Table 3).
The presence of MRSA with decreased susceptibility to
vancomycin and resistance to mupirocin and fusidic acid has
been documented [131,132].
The majority of healthcare facilities across the region have
infection control policies and committees that are modelled
according to internationally recommended guidelines. How-
ever, anecdotal reports suggest there are problems with
implementing high compliance and the judicious use of antibi-
otics, and this needs to be addressed. In addition, policies
are needed to regulate the availability of antibiotics and
reverse the current situation, whereby antibiotics can be
purchased across the counter without a prescription.
MGs: Lessons from the Hajj Pilgrimage
According to the WHO deﬁnition, ‘an organized or
unplanned event can be classiﬁed as a mass gathering if
TABLE 3. Methicillin-resistant Staph-
ylococcocus aureus (MRSA) multilo-
cus sequence types (ST) identiﬁed in
the Arabian Peninsula and Egypt
Country MRSA STs Reference
Saudi Arabia ST239a; ST241 [131,133]
Kuwait ST30a; ST80a; ST1; ST5; ST6; ST8; ST46; ST88; ST97; ST728; ST834; ST950 [134,135]
UAEb ST1a; ST5a; ST22a; ST80a; ST239a; ST6; ST79; ST88; ST113; ST361; ST779 [126]
Egypt ST30a; ST80a; ST1010 [136]
aPredominant STs.
bST239, ST22 and ST5 were predominant in 2003; and ST80, ST5 and ST1 were predominant in 2008.
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the number of people attending is sufﬁcient to strain the
planning and response resources of the community, state or
nation hosting the event’ (http://www.who.int/csr/Mass_
gatherings2.pdf). The Hajj is the largest annually recurring
MG, with 2–3 million pilgrims from around the world, includ-
ing many from countries with a high prevalence of infectious
disease. Thus, the risk of transmission of infectious diseases,
the occurrence of outbreaks and the possible global dissemi-
nation of infectious pathogens are major concerns. Respira-
tory and gastrointestinal infections have been identiﬁed as
common causes of hospital admissions during the Hajj
[137,138]. In 1987, there was Hajj-associated outbreak of
Neissieria meningitides serogroup A, and outbreaks caused by
N. meningitides serogroup W135 were recorded in the 2000
and 2001 seasons [139].
Managing this annual MG requires coordination and plan-
ning by all Saudi governmental sectors. The preventive
medicine committee under the auspices of the health minis-
ter oversees all key public health issues, and the strategies
for infection prevention are reviewed annually. During the
Hajj, attention to public health safety starts from arrival,
and the south terminal of Jeddah’s King Abdulazziz Interna-
tional Airport, which is the entry port for many pilgrims, is
designed to facilitate health screening for arriving pilgrims
who exhibit symptoms suggestive of infectious disease, and
ensure compliance with the mandatory meningococcal vac-
cination requirement. Free healthcare services are available
for all pilgrims, and in the vicinity of the Hajj sites there
are approximately 140 primary healthcare facilities and 24
hospitals providing 5000 beds, including almost 600 beds
for critical care [140]. More than 15 000 healthcare person-
nel are involved in the provision of healthcare services to
pilgrims, and public health teams conduct active surveillance
for respiratory diseases, gastroenteritis syndromes, viral
haemorrhagic fevers, and meningococcal disease. Real-time
analysis of collected data and collaboration with interna-
tional health agencies ensures that prompt intervention is
implemented when necessary. In recent years, Saudi Ara-
bia’s Hajj-related public health experience has been used as
a prototype for the planning and management of other
MGs [140].
Conclusion
Established and emerging infectious diseases, including those
associated with pathogens harbouring antibiotic resistance
genotypes, remain issues of public health concern in the
countries of the Arabian Peninsula and Egypt. The unique
population dynamics in the region set the stage for the dis-
semination of emerging pathogens across the region and
beyond. Public health measures, including mechanisms for
regional surveillance and reporting, as well as collaborative
research, are recommended to address these challenges.
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